Press Release

Date: October 28, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Code: 544558 Dear Sir/Madam, Sub: Press Release/ Media Release Enclosed herewith is the Press Release on the Unaudited Consolidated Financial Results of the Company for the quarter and half- year ended September 30, 2026. The same is also available on the website of the Company at www.fabtechnologies.com We request you to take the above information on record. Thank you. Yours faithfully, For Fabtech Technologies Limited Hemant Mohan Anavkar Executive Director DIN: 00150776 Encl.: As mentioned above Fabtech Technologies Ltd Q2 & H1 FY27 Press Release 28th October 2026 Fabtech Technologies Ltd. (Bloomberg Code: FABTECH:IN | NSE Code: FABTECH | BSE Code: 544558) has announced its financial results for Q2 & H1 FY27 today i.e. 28th October 2026. Financial Highlights (Consolidated): ₹ In Million Q2FY27 Q1FY27 Q2FY26 H1FY27 H1FY26 Revenue from Operations 920.9 749.8 1,214.8 1,670.7 1,894.9 EBITDA 155.7 74.1 332.5 229.8 279.8 EBITDA Margin (%) 16.0% 9.5% 26.8% 13.1% 14.5% Reported Profit After Tax 150.2 42.1 281.1 192.4 219.8 PAT Margin (%) 16.3% 5.6% 23.1% 11.5% 11.6% EPS in Rs. 3.38 0.95 8.68 4.33 6.79 Performance Summary: • The business enters H2 FY27 with its strongest execution runway of the year. The bulk of planned execution falls in this half, and revenue and profitability are expected to step up accordingly as project milestones are delivered. • Maximum of our orders / projects are covered with LCs, leaving little room for receivable risk and project execution. • UAE operations demonstrated strong order traction in Q2 FY27 despite regional challenges, with installation continuing under enhanced security and protective measures. • Africa initiatives are gaining momentum, including solutions for cell and gene therapy (CGT) and other advanced-technology facility projects. • Fabtech navigated geopolitical uncertainty and freight volatility across GCC markets while maintaining continuity of operations, deliveries and customer commitments despite higher costs. What affected our margins? • Higher freight and logistics costs due to shipping rate escalation mitigated by route re-routing, air uplift and war-risk surcharges. However, this impacted project execution costs and gross profit margins during H1 FY27. • Exceptional and non-recurring costs arising from enhanced site security, protective measures, standby and idle time, and extended project preliminaries impacted H1 FY27 profitability - not expected to recur at the same level in H2. • Higher raw material costs on a major reference vaccine project. Robust Order Book Visibility • Healthy Order Book of ~900 Cr. • Additional prospective orders from Africa and Saudi Arabia under discussion: Rs. 800-850 Cr. • The existing order position provides meaningful visibility over the next 12 months. Growth Outlook • Confident of achieving its FY27 operational PAT margin objective of 8–9%. • Deferred orders have been delayed in timing, with no cancellations recorded and customer engagement remaining active. About Fabtech Technologies Ltd, Fabtech Technologies Limited is a pharmaceutical engineering company providing specialised engineering, technology and turnkey solutions (including Design & Build) to the pharmaceutical, biotechnology and healthcare sectors. Over the past 25 years, Fabtech has developed capabilities across project design, technology transfer, pharmaceutical equipment manufacturing, turnkey project management, cleanroom infrastructure, cleanroom partitions and HVAC, containment solutions, pharmaceutical MEP, clean utilities, process piping, purified water systems and water-for injection systems. The company has executed 750+ projects across 62 countries, supported by a global workforce of 650+ professionals and regional operations across markets including the UAE, Saudi Arabia, Egypt, Nigeria, the UK, Algeria and Sri Lanka. With more than two decades of experience in pharmaceutical engineering, Fabtech has built capabilities spanning turnkey project management, cleanroom infrastructure, pharmaceutical MEP, process engineering, clean utilities, containment solutions and specialised pharmaceutical equipment. The company has executed projects across multiple geographies and continues to strengthen its international engineering and execution footprint. As pharmaceutical manufacturing capacity expands across emerging markets, Fabtech Technologies remains focused on leveraging its engineering expertise, international presence and execution capabilities to participate in the next phase of global healthcare infrastructure development. For further information, please contact KAPTIFY Consulting Fabtech Technologies Ltd. Investor Relations | Strategy | Consulting E: cs@fabtechnologies.com E: contact@kaptify.in | M: +91-845 288 6099 www.fabtechnologies.com www.kaptify.in Disclaimer This document may contain certain forward-looking statements within the meaning of applicable securities law and regulations. These statements include descriptions regarding the intent, belief or current expectations of the Company or its directors and officers with respect to the results of operations and financial condition of the Company. Such forward‐looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in such forward‐looking statements as a result of various factors and assumptions which the Company believes to be reasonable in light of its operating experience in recent years. Many factors could cause the actual results, performances, or achievements of the Company to be materially different from any future results, performances, or achievements. Significant factors that could make a difference to the Company’s operations include domestic and international economic conditions, changes in government regulations, tax regime and other statutes. The Company does not undertake to revise any forward‐ looking statement that may be made from time to time by or on behalf of the Company.